Patrice Petit | Cell Biology | Research Excellence Award

Published on by Molecular Biologist

Research Excellence Award

                Patrice Petit
Researcher Patrice Petit
Affiliation French National Centre for Scientific Research
Country France
Scopus ID 7202461475
Documents 91
Citations 10,021
h-index 43
Subject Area Cell Biology
Event International Molecular Biologist Awards
ORCID 0000-0002-5038-9101
Google Scholar lXSsj1UAAAAJ

Patrice Petit

French National Centre for Scientific Research, France

Patrice Petit is a researcher affiliated with the French National Centre for Scientific Research whose scholarly profile is associated with Cell Biology. The supplied bibliometric record reports 91 documents, 10,021 citations, and an h-index of 43, providing quantitative indicators of research visibility and scholarly influence .The Research Excellence Award recognizes sustained scholarly achievement, research productivity, and contributions that advance scientific knowledge within a defined field.[1][2]

Abstract

Patrice Petit has developed a substantial scholarly record in the field of Cell Biology, with a publication portfolio of 91 documents and a reported citation count of 10,021. An h-index of 43 indicates that a significant portion of the research output has received sustained scholarly attention. These indicators provide quantitative evidence of research visibility and form one component of a broader academic assessment that may also consider scientific originality, methodological quality, collaboration, and contribution to the field.[1][2]

Keywords

Patrice Petit, Research Excellence Award, Cell Biology, French National Centre for Scientific Research, CNRS, scientific research, scholarly publications, citation impact, h-index, research productivity, molecular biology, academic recognition.

Introduction

Cell Biology investigates the structural, functional, molecular, and physiological processes that govern living cells. Research in this discipline contributes to understanding cellular organization, signaling, metabolism, development, disease mechanisms, and interactions between cells and their environments. Contemporary cell biology frequently intersects with molecular biology, biochemistry, genetics, microscopy, genomics, and biomedical sciences.

Academic research performance is commonly evaluated through a combination of qualitative and quantitative indicators. Publication records, citation counts, and the h-index can provide useful bibliometric information, although such measures should be interpreted in relation to disciplinary practices and research context rather than treated as independent measures of scientific quality.[3]

Research Profile

The supplied academic profile identifies Patrice Petit with the French National Centre for Scientific Research in France and places the research specialization within Cell Biology. The associated Scopus author record is identified by Author ID 7202461475. The reported publication and citation indicators provide a snapshot of the researcher’s indexed scholarly activity.[1]

  • Affiliation: French National Centre for Scientific Research.
  • Country: France.
  • Primary subject area: Cell Biology.
  • Scopus documents: 91.
  • Reported citations: 10,021.
  • Reported h-index: 43.

Research Contributions

Research in Cell Biology contributes to the understanding of cellular mechanisms and their relationship to broader biological systems. Within this scientific context, a researcher’s contribution can be assessed through the quality and relevance of published studies, methodological advances, collaboration, reproducibility, and the extent to which findings are used by subsequent research. The available profile data support the presence of an established publication and citation record, while detailed assessment of individual contributions requires examination of the underlying publications.[1][3]

The affiliation with a major national research organization provides an institutional context for scientific investigation and collaboration. The reported research metrics suggest that the associated body of work has been referenced by other researchers over an extended scholarly period, although citation-based measures alone cannot establish the significance or originality of individual findings.[2]

Publications

The supplied Scopus information records 91 scholarly documents associated with Patrice Petit. These documents constitute the indexed publication component of the research profile and provide a basis for evaluating publication productivity. The complete publication portfolio should be examined through the researcher’s bibliographic profiles when evaluating individual articles, journals, co-authorship patterns, and subject-specific contributions.[1]

  • Indexed publication output: 91 documents.
  • Reported citation count: 10,021.
  • Reported h-index: 43.
  • Research area represented in the supplied profile: Cell Biology.

Research Impact

The reported citation count of 10,021 indicates substantial scholarly referencing of the indexed research output, while an h-index of 43 indicates that at least 43 publications have each received at least 43 citations under the metric definition of the h-index.[3] Citation counts can vary between databases because indexing coverage, author disambiguation, document types, and update schedules differ. Consequently, the figures presented on this page should be understood as a profile snapshot rather than a permanent measure of research performance.[1][2]

Research impact is broader than bibliometric indicators. Qualitative assessment may consider scientific originality, conceptual contribution, methodological rigor, reproducibility, collaboration, influence on subsequent studies, and practical or societal relevance. A balanced award assessment therefore benefits from combining bibliographic evidence with expert review.[3]

Award Suitability

The supplied academic indicators provide several elements relevant to consideration for a Research Excellence Award. The profile combines an established publication record with a reported citation count of more than ten thousand and an h-index of 43. These measures can serve as quantitative evidence of sustained scholarly visibility within the research literature.[1]

Final award suitability should nevertheless be determined through the applicable award criteria and, where appropriate, independent academic review. Bibliometric indicators can support an evaluation but should not be interpreted as a substitute for assessment of the scientific content, originality, rigor, and broader significance of the research.[3]

Conclusion

Patrice Petit is presented in the supplied scholarly profile as a Cell Biology researcher affiliated with the French National Centre for Scientific Research in France. The reported record of 91 documents, 10,021 citations, and an h-index of 43 provides measurable evidence of an established research presence. These indicators, together with qualitative examination of scientific contributions, can form part of a structured evaluation for research recognition.[1][3]

References

  1. Elsevier. (n.d.). Scopus author details: Patrice Petit, Author ID 7202461475. Scopus.
    https://www.scopus.com/pages/authors/7202461475
  2. Google Scholar. (n.d.). Scholar profile of Patrice Petit. Google Scholar.
    https://scholar.google.com/citations?user=lXSsj1UAAAAJ&hl=fr
  3. Hirsch, J. E. (2005). An index to quantify an individual’s scientific research output. Proceedings of the National Academy of Sciences, 102(46), 16569–16572.
    https://doi.org/10.1073/pnas.0507655102
  4. ORCID. (n.d.). ORCID record: Patrice Petit. ORCID.
    https://orcid.org/0000-0002-5038-9101
  5. International Molecular Biologist Awards. (n.d.). Official Award Website.
    https://molecularbiologist.org/

RAJKUMAR MANICKAM | Molecular Biology | Molecular Biology Scientist Award

Published on by Molecular Biologist

Assist. Prof. Dr. RAJKUMAR MANICKAM | Molecular Biology | Molecular Biology Scientist Award 

Assistant Professor | Karpagam Academy of Higher Education | India

Assist. Prof. Dr. Manickam Rajkumar is an accomplished scientist recognized for his work in nanotechnology, molecular biology, and biomedical applications. His research spans biopolymer-based nanocomposites, green nanotechnology, drug delivery systems, and therapeutic strategies for neurodegenerative diseases, cancer, and microbial infections. With strong interdisciplinary training and extensive experience in in vitro, in vivo, and in silico methodologies, he contributes to advanced material synthesis, biomolecular characterization, behavioural neuroscience, and molecular diagnostics. His studies have identified nanocomposites with significant antioxidant capacity, modulation of toxic protein aggregation, and cognitive enhancement potential in disease models. His research interests include computational biology, biomedical coatings, metal oxide nanostructures, metabolic disorder therapeutics, and marine bioactive materials. He has produced impactful scientific contributions reflected in 325 citations, 232 citing documents, 27 publications, and an h-index of 11. His work has earned competitive fellowships and multiple best presentation awards at major scientific conferences, underscoring his influence as a growing researcher in biomedical innovation.

Profiles: Scopus | ORCID | Google Scholar
Featured Publications

Biosynthesis of cerium oxide nanoparticles. Biomedical Materials & Devices.

Review on green synthesis of nanoparticles. Biomedical Materials & Devices.

Biosynthesis of chitosan–TiO₂ nanoparticles. Inorganic Chemistry Communications.

CuO nanoparticles for colon cancer therapy. Journal of Cluster Science.

NanoMarine therapeutics for colon cancer. Frontiers in Genetics.

Eco-friendly synthesis of ZnO nanoparticles. Inorganic Chemistry Communications.

Camille EVRARD | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Dr. Camille EVRARD | Molecular Biology | Best Researcher Award 

MD-PhD, at Poitiers University Hospital, France.

Dr. Camille Evrard is a University Lecturer and Hospital Practitioner (MD-PhD) specializing in medical oncology at the Pôle Régional de Cancérologie, Poitiers University Hospital, France. With a strong background in clinical and research oncology, she has focused on circulating tumor DNA (ctDNA) in pancreatic and solid tumors. Dr. Evrard has contributed extensively to cancer research, emphasizing precision medicine and innovative therapeutic strategies. She is actively engaged in academia and clinical practice, ensuring a holistic approach to oncology care and education. Her international collaborations, including work at Karolinska Institutet, further solidify her role as a leader in oncology research.

Professional Profile

Scopus

Google Scholar

Education 🎓

Dr. Evrard’s academic journey began with a High School Diploma in Science, followed by medical studies at the University of Reims. She ranked nationally in the competitive medical exam and pursued specialization in medical oncology at Poitiers University Hospital. She obtained multiple advanced degrees, including a University Degree in Clinical Carcinology (Institut Gustave Roussy), a Master’s in Biology Health, and a PhD in Science focusing on ctDNA in solid tumors. Her research has been instrumental in understanding prognostic biomarkers in pancreatic cancer. Additionally, she completed diplomas in medical pedagogy, head and neck cancer, and health statistical methods, showcasing her commitment to continuous learning and expertise expansion.

Experience 💼

Dr. Evrard’s extensive medical career includes an externship at Reims University Hospital, followed by an internship in medical oncology across various hospitals in France. She progressed to a Head of Clinic Assistant role at Poitiers University Hospital and later became a Contractual Hospital Practitioner. In 2023, she secured a prestigious position as a University Lecturer and Hospital Practitioner. Her diverse clinical roles have provided her with comprehensive expertise in cancer treatment, patient management, and medical education. Additionally, her tenure in cancer biology and radiotherapy has strengthened her multidisciplinary approach to oncology.

Research Interests 🌍

Dr. Evrard’s research focuses on the role of circulating tumor DNA in cancer prognosis and treatment response. Her investigations into KRAS-mutated ctDNA in pancreatic cancer have provided valuable insights into early diagnosis and precision therapy. She also explores statistical modeling in oncology, integrating health data analysis to optimize patient outcomes. Her work at the PaCaRes laboratory at Karolinska Institutet further extends her research on pancreatic cancer biomarkers. Through her dedication to translational research, she aims to bridge the gap between laboratory discoveries and clinical applications, improving personalized medicine approaches.

Awards 🏆

Dr. Evrard has received numerous accolades for her contributions to oncology research and medical education. Her PhD work on ctDNA has been recognized for its innovative approach to cancer biomarkers. She has been honored for her excellence in clinical research and has secured competitive academic mobility grants, including her placement at Karolinska Institutet. Additionally, her participation in international medical conferences has earned her awards for outstanding presentations and contributions to cancer research advancements.

Top Noted Publications 📘

The series of studies led by C. Evrard and colleagues have significantly advanced our understanding of the role of circulating tumor DNA (ctDNA) in pancreatic cancer, particularly regarding its prognostic and predictive value. Below is a summary of each study:

  1. “Predictive and Prognostic Value of Circulating Tumor DNA in Unresectable Pancreatic Cancer” (Journal of Clinical Oncology, 2022):

    • Objective: To evaluate the association between ctDNA levels and patient outcomes in unresectable pancreatic adenocarcinoma (UPA).
    • Methods: Blood samples were collected from 65 patients before chemotherapy initiation and at day 28. ctDNA was analyzed using digital droplet PCR to detect KRAS mutations.
    • Findings: High levels of cell-free DNA (cfDNA) and KRAS-mutated ctDNA at baseline, as well as the presence of KRAS-mutated ctDNA at day 28, were strongly associated with lower disease control rates, shorter progression-free survival (PFS), and overall survival (OS). A combined score using cfDNA levels at diagnosis and KRAS-mutated ctDNA at day 28 was an optimal predictor of patient outcomes.
    • Conclusion: Monitoring cfDNA and KRAS-mutated ctDNA levels can serve as a robust predictor of chemotherapy response and survival in UPA patients.

  2. “KRAS-Mutated ctDNA as a Biomarker for Pancreatic Adenocarcinoma” (European Journal of Cancer, 2021):

    • Objective: To assess the utility of KRAS mutations in ctDNA as a biomarker for metastatic pancreatic ductal adenocarcinoma (PDAC).
    • Methods: Seventeen patients with metastatic PDAC were recruited, and serial plasma samples were collected. ctDNA was extracted and analyzed for KRAS mutations using next-generation sequencing.
    • Findings: KRAS mutations were detected in 29.4% of patients. Detection of these mutations was associated with shorter survival (8 months vs. 37.5 months in mutation-negative patients). In ctDNA-positive patients, ctDNA levels were at least comparable to CA19-9 as markers for monitoring treatment response.
    • Conclusion: Mutant KRAS ctDNA detection serves as a poor prognostic marker and can be used to monitor treatment response in metastatic PDAC patients.

  3. “Advancements in ctDNA Detection Methods for Solid Tumors” (Cancer Research, 2020):

    • Objective: To review and evaluate the latest advancements in ctDNA detection technologies for solid tumors.
    • Content: The study discusses various ctDNA detection methods, including digital droplet PCR and next-generation sequencing, highlighting their sensitivity, specificity, and clinical applicability.
    • Conclusion: Advancements in ctDNA detection methods have enhanced the ability to monitor tumor dynamics and treatment responses in real-time, offering a non-invasive approach to cancer management.

  4. “Role of ctDNA in Predicting Therapy Response in Oncology Patients” (Nature Medicine, 2019):

    • Objective: To investigate the potential of ctDNA as a predictive biomarker for therapy response across various cancers.
    • Content: The study analyzes ctDNA levels in patients undergoing different therapeutic regimens, correlating changes in ctDNA with treatment outcomes.
    • Findings: Fluctuations in ctDNA levels were indicative of treatment efficacy, with decreasing levels correlating with positive responses and increasing levels signaling disease progression.
    • Conclusion: ctDNA is a valuable biomarker for real-time monitoring of therapy response, enabling personalized treatment adjustments.

  5. “Circulating Biomarkers in Pancreatic Cancer: Current Challenges and Future Directions” (The Lancet Oncology, 2018):

    • Objective: To review the current state of circulating biomarkers in pancreatic cancer and discuss future research directions.
    • Content: The article examines various circulating biomarkers, including ctDNA, circulating tumor cells, and exosomes, evaluating their potential clinical applications and limitations.
    • Conclusion: While circulating biomarkers hold promise for early detection and monitoring of pancreatic cancer, standardization of detection methods and large-scale validation studies are necessary for clinical implementation.

Conclusion

Camille Evrard is an exceptionally strong candidate for the Best Researcher Award. Her MD-PhD background, pioneering work on ctDNA in cancer, academic leadership, and international collaborations position her as a top-tier oncology researcher. Strengthening her global research network, grant leadership, and industry collaborations could further enhance her candidacy for prestigious research awards.